Building community following a rare kidney disease diagnosis: Ruchi’s story
Patient Voice spoke with Ruchi Ambike about her search to find community after being diagnosed with a rare disease. “I had just started my master’s program in 2001 when a …
Patient Voice spoke with Ruchi Ambike about her search to find community after being diagnosed with a rare disease. “I had just started my master’s program in 2001 when a …
Expanding Global Support: IgA Nephropathy Foundation Launches Go Global Network to Connect and Empower IgAN Patients Worldwide. By expanding our network to Canada, we are building a stronger, more connected …
WALL TOWNSHIP, NJ, UNITED STATES, March 18, 2025 /EINPresswire.com/ — The IgA Nephropathy (IgAN) Foundation marks its 20th anniversary in 2024, celebrating two decades of groundbreaking efforts in research, patient advocacy, and …
SAN DIEGO, Feb. 23, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of sparsentan for the treatment …
Ad hoc announcement pursuant to Art. 53 LR Read full press release here
On December 20, 2023, TARPEYO received full FDA approval for the new indication to reduce the loss of kidney function in adults with IgA Nephropathy (IgAN) who are at risk …
We want to tell you about an important research collaboration between IgA Nephropathy Foundation and the National Kidney Foundation (NKF). This research will have two phases. First, separate surveys of …
The IgA Nephropathy Foundation Launches First-Ever Cookbook Ahead of IgAN Awareness Day The Second Annual ‘IgAN Aware Day’ brings attention to the need for earlier diagnosis and treatments; cookbook offers …
May 25, 2022 – The IgA Nephropathy Foundation (IGAN Foundation), a nonprofit dedicated to supporting patients with a rare autoimmune kidney disease called IgA Nephropathy, today announced its formation of …
There is a lot of technical language around IgAN and it can seem confusing and overwhelming when receiving a diagnosis for yourself or a loved one. You may have many …
The NKF and IGANF conducted an EL-PFDD meeting on IgAN to inform the FDA on the patient perspective on living with this disease. Understanding the patient perspective will help the …
Abstract The randomized, controlled STOP-IgAN trial in patients with IgA nephropathy (IgAN) and substantial proteinuria showed no benefit of immunosuppression added on top of supportive care on renal function over …
Subscribe to our newsletter below!